JIMENEZ MORO, JOSE LUIS
 Distribuzione geografica
Continente #
NA - Nord America 373
EU - Europa 221
AS - Asia 137
SA - Sud America 1
Totale 732
Nazione #
US - Stati Uniti d'America 367
IT - Italia 59
SG - Singapore 49
GB - Regno Unito 43
CN - Cina 37
DE - Germania 27
IE - Irlanda 19
BE - Belgio 16
CH - Svizzera 13
FR - Francia 12
RU - Federazione Russa 12
JO - Giordania 11
ID - Indonesia 9
ES - Italia 8
MY - Malesia 8
TR - Turchia 8
HK - Hong Kong 7
CA - Canada 6
IN - India 4
UA - Ucraina 4
CZ - Repubblica Ceca 3
RO - Romania 2
VN - Vietnam 2
FI - Finlandia 1
KR - Corea 1
PE - Perù 1
SE - Svezia 1
SI - Slovenia 1
UZ - Uzbekistan 1
Totale 732
Città #
Chandler 73
Ann Arbor 38
Singapore 34
Princeton 29
Southend 27
Santa Clara 23
Council Bluffs 22
Dublin 19
Berlin 18
Ashburn 17
Boardman 17
Brussels 16
Houston 15
Turin 14
Piscataway 12
Jakarta 9
Beijing 8
Izmir 7
Woodbridge 7
New York 6
Falls Church 5
San Donato Milanese 5
Torino 5
Lake Forest 4
Madrid 4
Menlo Park 4
Milan 4
Norwalk 4
Zurich 4
Basking Ridge 3
Bern 3
Montréal 3
Redwood City 3
Washington 3
Colmenar Viejo 2
Dearborn 2
Dong Ket 2
Guangzhou 2
Las Vegas 2
Lutherville-Timonium 2
Miami 2
Redmond 2
Seattle 2
Ulm 2
Victoria 2
Wettswil / Wettswil (Dorf) 2
Yubileyny 2
Absecon 1
Anaheim 1
Augusta 1
Buffalo 1
Cambridge 1
Changsha 1
Chicago 1
Estavayer-le-lac 1
Galati 1
Hanover 1
Helsinki 1
Hunedoara 1
Istanbul 1
Lago 1
Lima 1
Ljubljana 1
Nanjing 1
Olomouc 1
Pietra Ligure 1
Rome 1
Shanghai 1
Shaoxing 1
Shijiazhuang 1
Staten Island 1
Tianjin 1
Toronto 1
Viterbo 1
Wilmington 1
Wuxi 1
la Garriga 1
Totale 521
Nome #
Innovative adaptive designs in oncology clinical trials with drug combinations 140
Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents 120
Quantifying treatment differences in confirmatory trials under non-proportional hazards 83
A Bayesian seamless phase I-II trial design with two stages for cancer clinical trials with drug combinations. 73
Response to comments on “Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects” by José L. Jiménez, Viktoriya Stalbovskaya and Byron Jones, Pharmaceutical Statistics, 2019; 18:287-303, DOI: 10.1002/pst.1923 67
Properties of the weighted log-rank test in the design of confirmatory studies with delayed effects 59
Designs of Early Phase Cancer Trials with Drug Combinations 59
A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching 56
Design and analysis of group-sequential clinical trials based on a modestly weighted log-rank test in anticipation of a delayed separation of survival curves: A practical guidance 29
Stratified modestly weighted log-rank tests in settings with an anticipated delayed separation of survival curves 29
A Bayesian adaptive design for dual-agent phase I-II oncology trials integrating efficacy data across stages 26
Combining cytotoxic agents with continuous dose levels in seamless phase I-II clinical trials 25
Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value? 18
Totale 784
Categoria #
all - tutte 3.228
article - articoli 2.744
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 191
Totale 6.163


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202029 0 0 0 0 0 2 2 5 8 4 5 3
2020/202192 7 3 1 2 3 0 1 2 5 62 4 2
2021/2022109 1 3 0 2 36 2 1 1 8 2 17 36
2022/2023236 20 38 4 21 45 26 8 15 26 1 12 20
2023/2024105 3 18 6 4 6 5 4 15 10 6 3 25
2024/2025130 3 44 10 37 22 14 0 0 0 0 0 0
Totale 784